Given the intratumoral heterogeneity of TAM polarization in ovarian cancer, a strategic combination of macrophage-targeted therapies, such as CSF1R and TREM2 inhibitors, with immunotherapies holds promise for improving clinical outcomes. Here, TREM2 is linked to ovarian carcinoma.